Press Releases

08-06-2021

Eckert & Ziegler: Affiliate Receives Additional NIAID Funding to Advance Pharmaceutical Development

03-06-2021

Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

18-05-2021

Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic

17-05-2021

​​​​​​​Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business

28-04-2021

Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer

16-04-2021, 11:01 CEST (Ad hoc press release)

​​​​​​​Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM

14-04-2021

​​​​​​​Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin

12-04-2021, 21:12 CEST (Ad hoc press release)

Eckert & Ziegler Receives Technetium Generator Licenses for Brazil

25-03-2021, 19:52 CET (Ad hoc press release)

​​​​​​​Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.

24-03-2021, 14:09 CET (Ad hoc press release)

​​​​​​​Eckert & Ziegler Divests From Tumour Irradiation Business

17-03-2021, 23:49 CET (Ad hoc press release)

Eckert & Ziegler 2020: Earnings higher than expected

12-02-2021

Eckert & Ziegler to Start Development of Radioisotope Production Facility in Jintan, PR China

10-02-2021

Eckert & Ziegler Wins Again Award for Excellent Training Quality

08-02-2021

Eckert & Ziegler Wins Order for Hot Cell Construction from Dutch Research Center

04-02-2021, 19:28 CET (Ad hoc press release)

Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

28-01-2021

​​​​​​​Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in USA

12-01-2021

Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care